CorrectSequence Therapeutics
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Distrct Shanghai No.99 Haike Rd, Pudong,...Website
www.correctsequence.comRevenue
$7.3 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About CorrectSequence Therapeutics
CorrectSequence Therapeutics is a pharmaceutical company specializing in innovative gene editing technologies, particularly base editing and gene therapy. Their mission is to help individuals suffering from severe diseases by developing advanced therapeutic solutions. The company aims to be a leading player in the gene editing field, both in China and globally. They focus on patient-centric values, emphasizing responsibility, collaboration, and innovation in their approach.Explore more
CorrectSequence Therapeutics Org Chart
PL
Director of Translational Science
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CorrectSequence Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
CorrectSequence Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when CorrectSequence Therapeutics launches new products
Funding: Get notified immidiatlly once CorrectSequence Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check out if CorrectSequence Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at CorrectSequence Therapeutics
Check if CorrectSequence Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on CorrectSequence Therapeutics recently announced quarterly report
Click to see if CorrectSequence Therapeutics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
CorrectSequence Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CorrectSequence Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CorrectSequence Therapeutics.
CorrectSequence Therapeutics News & Media
Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia. SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- On September 7, 2026, Shanghai, Cell Stem Cell published...High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
CorrectSequence Therapeutics Reports Positive 15-Month Follow-Up Data for CS-206 SHANGHAI, June 2, 2026 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for severe diseases, announced that the first sickle cell disease (SCD) patient being treated in China with its high-precision base-editing therapy CS-206 has remained free of vaso-occlusive crises (VOCs) for more than 15 months followThe World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a...High-Precision Base Editing Clinical Treatment for Sickle Cell Disease -- CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient
SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the first sickle cell...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CorrectSequence Therapeutics
Sign Up For FreeTo access detailed company insights
CorrectSequence Therapeutics is a pharmaceutical company specializing in innovative gene editing technologies, particularly base editing and gene therapy. Their mission is to help individuals suffering from severe diseases by developing advanced therapeutic solutions. The company aims to be a leading player in the gene editing field, both in China... Read More
